Earnings ·
Exagen reports Q3 revenue of $18.4M, up 7%, with net loss narrowing to $6.3M
XGNExagen Inc.
Exagen Inc. reported third-quarter 2026 financial results showing total revenue grew 7% to $18.4 million compared to the prior-year period. For the nine months ended September 30, 2026, revenue increased 11% to $55.7 million. The company posted a net loss of $6.3 million for the quarter, a reduction from $7.1 million in Q3 2025, while adjusted EBITDA improved by over 30%. Exagen reiterated its full-year 2026 revenue guidance of $72 million to $75 million and ended the quarter with approximately $28.1 million in cash and cash equivalents. The company operates as a precision diagnostics provider specializing in autoimmune disease testing.